MarketVIEW: Nipah virus vaccines (CAT: VAMV081)

Product Name	:	**MarketVIEW:** Nipah virus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (~150 slides.pdf) + MS-Excel forecast model(s) (.xls)
Therapeutic Area	:	Novel viral endemic vaccines
Publication date	:	February 2021
Catalogue No	:	VAMV081

Background

Nipah virus infection (NiV) is caused by Nipah Virus, an RNA virus and member of the *Paramyxoviridae* family (genus *Henipavirus*). The virus, first isolated in 1999 following an outbreak of encephalitis and acute respiratory illness in Malaysia and Singapore, has registered around 600 infections to date but has pandemic potential according to the World Health Organisation. NiV infected patients (all ages susceptible) usually present with fever, headache, myalgia, vomiting and sore throat. Some patients develop more severe symptoms such as atypical pneumonia and severe respiratory problems, which can be fatal (CFR >70%). Fruit bats of the *Pteropus* genus are the natural hosts of NiV which can be transmitted to humans via pigs as an intermediate host, but human-to-human transmission (especially nosocomial) has also been documented in notable India and Bangladesh outbreaks.

Work is underway to develop a preventative Nipah virus vaccine mainly as part of **CEPI** funded efforts at many organisations, both in the not-for-profit and commercial sectors. For example, in May 2018 a consortium involving Emergent Biosolutions, PATH, Profectus and various universities received $25m over five years to develop a HeV-sG vaccine. Other initiatives are underway.

This **MarketVIEW** product is a comprehensive Executive Presentation (~145 slides) and MS-Excel forecast model which investigates the commercial potential of a putative Nipah virus vaccine in all relevant target groups (preventative and emergency scenarios) to 2035. The potential of public (stockpile) and potential private markets are explored. There are detailed case study analyses other vaccine procurement/deployment scenarios to serve as guidance with all assumptions clearly outlined. A thorough review of current disease background/epidemiology and R&D competitive environment are also included. This product is ideally suited to organisations wishing to quantify the Nipah virus vaccine opportunity.

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Nipah virus vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral based-pathogens, especially Ebola and Lassa virus has also been utilised.

PRODUCT CONTENTS:
Published February 2021 (CAT No: VAMV081)

****This product is a summary presentation (.pdf), a forecast model (.xls)

Contents – Summary presentation (.pdf)[1]

Contents
Author's notes
Executive summary
[SECTION 1] Nipah virus vaccines: key commercial model outputs
[SECTION 2] Nipah virus: disease background
[SECTION 3] Nipah virus: disease epidemiology
[SECTION 4] Nipah virus: summary of vaccine development
[SECTION 5] Nipah virus vaccines: modelling commercial potential
[SECTION 6] Case study analyses
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~150 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Worksheets = >30 interconnected

---

[1] Full contents i.e. title per slide is available upon request

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   **Tel.** +44(0)1279 927049   **e-mail: info@vaczine-analytics.com**

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o FULL PRODUCT - USD **$8,995.00**/ GBP **£6995.00**# (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to the final invoice total
 # - indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary

HOW TO ORDER:

To order, please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.


VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics ® and the **"spiral logo"** are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 927049 **e-mail:** info@vaczine-analytics.com

BIBLIOGRAPHY

References – available upon request

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).

2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.

3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.

4. If not purchased on line invoices are payable within **thirty days** of the invoice date.

5. All proposals are quoted in **$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.

6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
A division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 927049
E-mail: info@vacZine-analytics.com

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   **Tel.** +44(0)1279 927049   **e-mail:** info@vaczine-analytics.com